HURN Stock Analysis: Huron Consulting | NASDAQ
Consulting Services | NASDAQ, USA | Market Cap: 2.805m USD | 12M Return: 15.1% | US4474621020 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 39.5M
EPS Trend: 99.1%
Qual. Beats: 4
Rev. Trend: 99.0%
Qual. Beats: 4
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Huron Consulting Group Inc. (NASDAQ: HURN) is a Chicago-based global professional services firm that operates through three core segments: Healthcare, Education, and Commercial. The company delivers a broad portfolio of services spanning financial and operational performance improvement, digital and technology consulting (including enterprise systems, data management, and AI/automation), organizational transformation, revenue cycle managed services, and strategy and innovation advisory.
In addition to its consulting engagements, Huron markets proprietary software products-most notably the Huron Research suite, which supports research administration and compliance for academic and healthcare institutions. Its client base spans healthcare, education, financial services, industrials and manufacturing, energy and utilities, and the public sector, serving both U.S. and international markets. Founded in 2002 and publicly listed since 2004, Huron sits within the Industrials sector under the Research & Consulting Services sub-industry, a category that typically generates revenue through a mix of fee-based consulting engagements, managed services contracts, and recurring software licenses.
- Healthcare segment growth driven by EHR and revenue cycle managed services
- Education segment expands on Huron Research Suite software adoption
- Commercial consulting demand rises with M&A and restructuring activity
| Net Income: 115.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -2.32 > 1.0 |
| NWC/Revenue: 12.15% < 20% (prev 15.65%; Δ -3.50% < -1%) |
| CFO/TA 0.11 > 3% & CFO 178.5m > Net Income 115.6m |
| Net Debt (866.0m) to EBITDA (234.2m): 3.70 < 3 |
| Current Ratio: 1.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (16.4m) vs 12m ago -7.79% < -2% |
| Gross Margin: 30.49% > 18% (prev 32.21%; Δ -1.72% > 0.5%) |
| Asset Turnover: 115.8% > 50% (prev 105.1%; Δ 10.70% > 0%) |
| Interest Coverage Ratio: 4.89 > 6 (EBIT TTM 196.0m / Interest Expense TTM 40.1m) |
| A: 0.13 (Total Current Assets 529.8m - Total Current Liabilities 309.9m) / Total Assets 1.64b |
| B: 0.36 (Retained Earnings 599.4m / Total Assets 1.64b) |
| C: 0.13 (EBIT TTM 196.0m / Avg Total Assets 1.56b) |
| D: 0.31 (Book Value of Equity 384.8m / Total Liabilities 1.26b) |
| Altman-Z'' = 3.23 = A |
| DSRI: 0.98 (Receivables 457.4m/399.5m, Revenue 1.81b/1.56b) |
| GMI: 1.06 (GM 32.21% / 30.49%) |
| AQI: 1.01 (AQ_t 0.65 / AQ_t-1 0.64) |
| SGI: 1.16 (Revenue 1.81b / 1.56b) |
| TATA: -0.04 (NI 115.6m - CFO 178.5m) / TA 1.64b) |
| Beneish M = -2.87 (Cap -4..+1) = A |
As of October 20, 2026, the stock is trading at USD 174.72 with a total of 159,650 shares traded. Over the past week, the price has changed by +0.86%, over one month by +9.76%, over three months by +55.13% and over the past year by +15.10%.
Current recommended Stop Loss: 167.80 (which is 4% or 1.2 ATR below the current price).
Huron Consulting has received a consensus analysts rating of 4.80. Therefore, it is recommended to buy HURN.
- StrongBuy: 4
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 190.8 | 9.2% |
P/E Trailing = 26.5557
P/E Forward = 15.5039
P/S = 1.5814
P/B = 6.6144
P/EG = 1.5199
Revenue TTM = 1.81b USD
EBIT TTM = 196.0m USD
EBITDA TTM = 234.2m USD
Long Term Debt = 489.7m USD (from longTermDebt, last fiscal year)
Short Term Debt = 29.8m USD (from shortTermDebt, last quarter)
Debt = 897.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 32.7m
Net Debt = 866.0m USD (calculated: Debt 897.2m - CCE 31.2m)
Enterprise Value = 3.67b USD (2.81b + Debt 897.2m - CCE 31.2m)
Interest Coverage Ratio = 4.89 (Ebit TTM 196.0m / Interest Expense TTM 40.1m)
EV/FCF = 22.80x (Enterprise Value 3.67b / FCF TTM 161.0m)
FCF Yield = 4.39% (FCF TTM 161.0m / Enterprise Value 3.67b)
FCF Margin = 8.89% (FCF TTM 161.0m / Revenue TTM 1.81b)
Net Margin = 6.38% (Net Income TTM 115.6m / Revenue TTM 1.81b)
Gross Margin = 30.49% ((Revenue TTM 1.81b - Cost of Revenue TTM 1.26b) / Revenue TTM)
Gross Margin QoQ = 32.51% (prev 27.85%)
Tobins Q-Ratio = 2.23 (Enterprise Value 3.67b / Total Assets 1.64b)
Interest Expense / Debt = 4.47% (Interest Expense 40.1m / Debt 897.2m)
Taxrate = 25.88% (40.3m / 155.9m)
NOPAT = 145.3m (EBIT 196.0m * (1 - 25.88%))
Current Ratio = 1.71 (Total Current Assets 529.8m / Total Current Liabilities 309.9m)
Debt / Equity = 2.33 (Debt 897.2m / totalStockholderEquity, last quarter 384.8m)
Debt / EBITDA = 3.70 (Net Debt 866.0m / EBITDA 234.2m)
Debt / FCF = 5.38 (Net Debt 866.0m / FCF TTM 161.0m)
Total Stockholder Equity = 452.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.39% (Net Income 115.6m / Total Assets 1.64b)
RoE = 25.53% (Net Income TTM 115.6m / Total Stockholder Equity 452.7m)
RoCE = 20.80% (EBIT 196.0m / Capital Employed (Equity 452.7m + L.T.Debt 489.7m))
RoIC = 10.90% (NOPAT 145.3m / Invested Capital 1.33b)
WACC = 3.86% (E(2.81b)/V(3.70b) * Re(4.03%) + D(897.2m)/V(3.70b) * Rd(4.47%) * (1-Tc(0.26)))
Discount Rate = 4.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -90.16 | Cagr: -6.24%
[DCF] Terminal Value 73.92% ; FCFF base≈168.3m ; Y1≈154.5m ; Y5≈136.7m
[DCF] Fair Price = 81.93 (EV 2.17b - Net Debt 866.0m = Equity 1.30b / Shares 15.9m; r=8.35% [WACC [floored]]; 5y FCF grow -10.24% → 2.50% )
EPS Correlation: 99.09 | EPS CAGR: 24.18% | SUE: 2.23 | # QB: 4
Revenue Correlation: 99.00 | Revenue CAGR: 11.43% | SUE: 1.83 | # QB: 4
EPS current Quarter (2026-09-30): EPS=2.47 | Chg30d=+0.00% | Revisions=+0% | Analysts=5
EPS current Year (2026-12-31): EPS=9.20 | Chg30d=+0.00% | Revisions=+57% | GrowthEPS=+17.5% | GrowthRev=+12.6%
EPS next Year (2027-12-31): EPS=10.59 | Chg30d=+0.00% | Revisions=+62% | GrowthEPS=+15.1% | GrowthRev=+9.0%
[Analyst] Revisions Ratio: +56% (up=11, down=2)